Introduction

Patient-Derived Xenografts (PDX) have redefined translational oncology by directly linking preclinical research to clinical decision-making. Beyond their role in drug discovery, PDX models are increasingly employed in co-clinical trials, where preclinical studies are conducted in parallel with patient treatment, and in personalized medicine workflows, where PDX serve as avatars for individual patients. These approaches create a feedback loop between laboratory and clinic, improving predictive accuracy and guiding therapeutic strategies.

PDX in Co-Clinical Trials

Co-clinical trials operate on the principle of simultaneous testing: patients enrolled in a clinical trial have tumor tissue implanted into mice, creating parallel PDX cohorts. These xenografts are subjected to the same investigational therapy or alternative regimens to anticipate resistance, validate biomarkers, and inform adaptive trial designs. For example, in lung cancer and breast cancer trials, PDX avatars have been used to predict which subgroups respond best to targeted therapies. Data generated in real time from the xenograft arm helps refine patient stratification and optimize dosing schedules.

Personalized Medicine Workflows

In a personalized medicine context, PDX act as patient avatars, providing a living system that mirrors the individual’s tumor biology. Once established, these xenografts are exposed to multiple therapeutic options, effectively conducting in vivo drug sensitivity screens. Oncologists can then use these results to guide treatment selection for the patient, especially in cases where standard-of-care regimens have failed. Although engraftment time (weeks to months) may limit immediate application, PDX-based personalized workflows are invaluable for identifying second-line or salvage therapies.

Advantages of PDX in Precision Oncology

• Patient-Specific Predictivity: Drug responses in PDX often recapitulate those in the originating patient.
• Biomarker Development: Co-clinical trials allow biomarker discovery that is directly translatable to clinical endpoints.
• Adaptive Treatment Strategies: Results from xenografts enable real-time adjustments in trial design and personalized care.
• Mechanistic Insights: Resistance mechanisms can be uncovered before they manifest clinically.

Challenges and Considerations

Despite their potential, several hurdles remain. The time required for PDX establishment may preclude first-line therapeutic decision-making. Costs and resource requirements are substantial, limiting widespread use in routine clinical practice. Additionally, murine stromal replacement may influence drug penetration and microenvironmental signaling. To address these challenges, efforts are underway to accelerate engraftment rates, expand access to xenograft biobanks, and integrate complementary systems such as organoids.

Future Directions

The integration of multi-omics technologies, high-throughput drug screening, and computational modeling into PDX workflows is expected to enhance their predictive power. Hybrid platforms combining PDX with organoid or ex vivo culture systems may reduce engraftment time while preserving patient-specific fidelity. As co-clinical trial frameworks expand, PDX models will become central to precision oncology, ensuring that laboratory insights are rapidly and effectively translated into patient benefit.